Purple Biotech (PPBT) Cash & Equivalents (2014 - 2026)

Purple Biotech (PPBT) has 13 years of Cash & Equivalents data on file, last reported at $5.6 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 3.55% year-over-year to $5.6 million in Q1 2026; TTM through Mar 2026 was $5.6 million, a 3.55% decrease from a year earlier, with the FY2025 full-year figure at $8.7 million, up 927.95% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $5.6 million, down from $8.7 million in the prior quarter.
• Over the last five years, Cash & Equivalents for PPBT reached as high as $23.5 million in Q1 2022 and fell as low as $848000.0 in Q4 2024.
• Historically, Cash & Equivalents has averaged $11.1 million across 5 years, with a median of $10.0 million in 2024.
• Across the five-year window, Cash & Equivalents plunged 94.15% in 2024 and soared 927.95% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $15.0 million in 2022, then decreased by 3.6% to $14.5 million in 2023, then plunged by 94.15% to $848000.0 in 2024, then surged by 927.95% to $8.7 million in 2025, then tumbled by 36.14% to $5.6 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $5.6 million in Q1 2026, $8.7 million in Q4 2025, and $9.6 million in Q3 2025.